CARLSBAD, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals (Nasdaq: ISIS) announces the following Webcast:

     What:     Isis Pharmaceuticals discusses its third quarter
               financial results and new developments in joint ventures with
               Elan.



     When:     Wednesday, November 6, 2002 @ 5:30 am Pacific Time /
               8:30 am Eastern Time



     Where:    http://www.firstcallevents.com/service/ajwz369610280gf12.html



     How:      Live over the Internet -- Simply log on to the web at the
               address above.



     Contact:  Karen Lundstedt of Isis Pharmaceuticals, Inc., +1-760-603-3880.

If you are unable to participate during the live webcast, the call will be archived on the Web site www.isispharm.com , or the address above.

Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The company has commercialized its first product, Vitravene® (fomivirsen), to treat CMV-induced retinitis in AIDS patients. In addition, Isis has 13 antisense products in its development pipeline with two in late-stage development and six in Phase II human clinical trials. Affinitac™, an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III trials for Crohn's disease. Isis has a broad patent estate as the owner or exclusive licensee of more than 1,000 issued patents worldwide. Isis' GeneTrove™ division uses antisense to assist pharmaceutical industry partners in validating and prioritizing potential gene targets through customized services. Ibis Therapeutics™ is a division focused on the discovery of small molecule drugs that bind to RNA. Additional information about Isis is available at www.isispharm.com .

(Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/EN/default.asp and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to webcastsupport@tfprn.com.)

Make Your Opinion Count - Click Here

http://tbutton.prnewswire.com/prn/11690X45666358

SOURCE Isis Pharmaceuticals, Inc.